Proteins from Avastin® (bevacizumab) Show Tyrosine Nitrations for which the Consequences Are Completely Unclear

Avastin® (bevacizumab) is a protein drug widely used for cancer treatment although its further use is questionable due to serious side effects reported. As no systematic proteomic study on posttranslational modifications (PTMs) was reported so far, it was the aim of the current study to use a gel-based proteomics method for determination of Avastin®-protein(s)

Identified nitrotyrosine or aminotyrosine modifications in Avastin by HCT and Orbitrap: the software proposes possible modifications on the peptide and subsequently assigns them to “measured m/z”. The theoretical m/z indicates the peptide mass with expected modifications.

a<p>Avastin Heavy chain</p>b<p>Avastin Light chain</p>c<p>Both nitrotyrosine and aminotyrosine modifications are identified at the same Y192 site of Spot 6.</p>d<p>given in Da</p

The modifications verified by HCT and Orbitrap.

<p>The modifications verified by HCT and Orbitrap.</p

2-DE image of Avastin® is shown providing assignments of identified protein spots.

<p>2-DE image of Avastin® is shown providing assignments of identified protein spots.</p